Navigation Links
Best Cyclotron Systems/Best Theratronics and MIT/INFN, a Part of the DAEdALUS Collaboration, are Developing a Range of Low to High Power, Next Generation Cyclotrons
Date:6/17/2013

Vancouver, British Columbia, Canada (PRWEB) June 17, 2013

BCSI and BTL have invested in a Multi Million USD test and research facility, the only one of its kind in the world, for these scientists to design, develop and test prototype concepts for these Cyclotrons. This research will help BCSI and BTL to introduce a new generation of modern low to high power Cyclotrons next year. Currently, BCSI and BTL are expecting nearly 50 Million USD worth of orders for new Cyclotrons, in addition to the 20 Million USD worth of orders for 70 MeV and 15 MeV Cyclotrons, to be shipped this year. These are the result of BTL and BCSI investing more than 20 Million USD in product, research, design, development and manufacturing of these unique modern Cyclotrons, using the latest in technological advancements.

BCSI and BTL are hosts to a Massachusetts Institute of Technology (MIT)/Italian National Laboratory of Legnaro (INFN) experimental group, part of the DAEdALUS Collaboration (http://www2.lns.mit.edu/~conrad/daedalus.html) aimed at world-class neutrino experiments using a new generation of high-current cyclotrons. The DAEdALUS Group has installed and is currently testing its new ion source, developed at the Catania INFN laboratory, at the TeamBest Vancouver test and research facility. Professor Janet Conrad of the MIT Department of Physics reported that, “…It is nice to see basic science and applications of physics move forward hand-in-hand so productively.”

The key feature of the high current accelerator is the use of singly-ionized molecules of hydrogen (H2+), that are subsequently converted to two protons (2H+), and delivered to high-power neutrino-production targets.

The BCSI and BTL test and research facility has assembled a new well-instrumented Cyclotron Central Region Test Stand. This comprehensive research facility produces, transports and injects particles into a flexibly designed test cyclotron, capable of accelerating ions up to a maximum of 1 MeV. This low energy allows ion source and injection dynamics to be studied together with the first few turns of the actual cyclotron, without generating any radioactivity. Consequently, the MIT/INFN teams can test their developments and designs at an early stage before finalizing the details of their much larger accelerators.

The test stands are used to confirm and validate Ion Source and Injection Systems for all the TeamBest Cyclotrons, such as the B15, B25, B35 and the B70. The BCSI and BTL new test stand is arguably the smallest cyclotron in the world today, and with it and the DAEdALUS group, TeamBest is contributing to one of the largest cyclotron design teams in the world. The test stand experiments optimize the accelerator characteristics before final products are manufactured and delivered to customers. This will reduce commissioning time at the customer site and installation will be executed as planned.

BTL’s president, Krishnan Suthanthiran, has said, “There is so much synergy between our research and development and our science friends! We are pleased that they are at our test and research facility in Vancouver.“ The BCSI Director of Operations and Research, Dr. Richard Johnson reports that, “The ideas that DAEdALUS has brought to our laboratory will surely be applied to our health care equipment development.”

About Best Theratronics
Best Theratronics (BTL) was founded more than 60 years ago with their invention of the first commercial Gamma Beam Teletherapy (GBT) machine for treating cancer and non-malignant tumors with radiation. Canada issued a special stamp to commemorate this breakthrough invention. BTL has been manufacturing and supplying these machines that are considered the gold standard and work horses of radiation oncology departments globally since its invention and commercialization. In addition, BTL manufactures a range of Blood Irradiators, Cyclotrons and other products. For more information, please visit http://www.theratronics.com.

About Best Medical International
Best Medical International (BMI) has served the medical community with the highest quality products and unparalleled customer service for more than 35 years. BMI, headquartered in Springfield, VA, USA encompasses a family of medical companies known as TeamBest, with a proven track record of innovation, quality and service. TeamBest provides solutions for External Beam Radiation Therapy and Brachytherapy including: Best® Iodine-125 and Palladium-103 seeds; Brachytherapy accessories, Radiotherapy and diagnostic imaging devices, Gold fiducial markers, MOSFET patient dosimetry, patient immobilization, cardiovascular brachytherapy and medical physics/QA instrumentation, repair and calibration.

http://www.bestcyclotron.com
http://www.theratronics.com
http://www.teambest.com

CONTACT:

Krishnan Suthanthiran
Founder & President of TeamBest Companies
krish@teambest.com

Richard Johnson
Director of Cyclotron Research Operations
richard.johnson(at)teambest(dot)com
(604)657-6694

Read the full story at http://www.prweb.com/releases/2013/6/prweb10836541.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
2. Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor
3. IU Simon Cancer Center joins WellPoint in developing health care solutions
4. Surprising results for use of dialysis for kidney failure in developing world
5. Pediatric tumors traced to stem cells in developing brain​​
6. Researchers developing new multiple sclerosis drug that can be taken orally
7. Researchers developing bioadhesive gel to protect women from HIV and HSV infections
8. Undergrads invent cell phone screener to combat anemia in developing world
9. LA BioMed investigator, Dr. Yutaka Niihara, developing novel cellular therapy
10. Global sleeplessness epidemic affects an estimated 150 million in developing world
11. By studying animal health, researchers find improved ways for developing, testing cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: